search
Neko Health
Trends
- 1Spotify billionaire Daniel Ek brings his body scan startup to the US▼Spotify billionaire’s body scan startup has come to America
Daniel Ek, the Spotify co-founder and billionaire, has expanded his health-tech startup Neko Health to the United States. The company offers full-body scans aimed at early detection of health problems, and its arrival in America marks its first move beyond Europe. The launch is drawing attention as a test of whether preventive scanning can catch on in the US market.
- 2Spotify billionaire's body scan startup Neko Health expands to the US▼Spotify billionaire’s body scan startup has come to America Farooq Abbasi, an investor in Neko Health, talked to Equity
Neko Health, the preventive health startup co-founded by Spotify billionaire Daniel Ek, has launched in the United States. The company offers full-body scans aimed at early detection of health issues. Investor Farooq Abbasi discussed the company's growth plans and the broader health tech opportunity, drawing attention to the expanding market for proactive, scan-based healthcare services in America.
- 3Daniel Ek's Body Scanning Startup Neko Health Launches in the US▼Neko Health, the Body Scanning Startup Founded by Daniel Ek, Arrives in America
Neko Health, the preventive health startup co-founded by Spotify chief Daniel Ek, has expanded to the United States. The company offers full-body scans designed to detect early signs of disease, and it previously launched services in Europe. Its American arrival marks a significant step for the emerging preventive diagnostics sector, drawing attention to Ek's ventures beyond music streaming.
- 4Neko Health brings full-body scans to the US▼Is Neko Health’s body scan worth it? Spotify billionaire’s startup has come to America
Neko Health, the preventive health startup co-founded by Spotify billionaire Daniel Ek, has launched in the United States, prompting debate over whether its full-body scan is worth the price. The service uses advanced imaging to screen for early signs of disease, and commentary so far centres on cost, accessibility and whether the technology offers real medical value.